151 related articles for article (PubMed ID: 27492732)
1. Charlson comorbidity index predicts poor outcome in CML patients treated with tyrosine kinase inhibitor.
Uemura M; Imataki O; Kawachi Y; Kawakami K; Hoshijima Y; Matsuoka A; Kadowaki N
Int J Hematol; 2016 Nov; 104(5):621-627. PubMed ID: 27492732
[TBL] [Abstract][Full Text] [Related]
2. Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor.
Ono T; Takahashi N; Kizaki M; Kawaguchi T; Suzuki R; Yamamoto K; Ohnishi K; Naoe T; Matsumura I
Cancer Sci; 2020 Oct; 111(10):3714-3725. PubMed ID: 33404088
[TBL] [Abstract][Full Text] [Related]
3. EUTOS CML prognostic scoring system predicts ELN-based 'event-free survival' better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate.
Uz B; Buyukasik Y; Atay H; Kelkitli E; Turgut M; Bektas O; Eliacik E; Isik A; Aksu S; Goker H; Sayinalp N; Ozcebe OI; Haznedaroglu IC
Hematology; 2013 Sep; 18(5):247-52. PubMed ID: 23540886
[TBL] [Abstract][Full Text] [Related]
4. [Clinical significance of Sokal, Hasford and EUTOS prognostic scoring systems in chronic myeloid leukemia].
Feng G; Wang J; Jiang Y; Li Y; Ding M; Wang N; Wang X
Zhonghua Xue Ye Xue Za Zhi; 2014 Aug; 35(8):743-6. PubMed ID: 25152126
[TBL] [Abstract][Full Text] [Related]
5. A comparative study of Hasford score and Sokal index in prognostication of the novo chronic myeloid leukemia patients and a search for new prognostic markers.
Sinha SK; Sinha S; Mandal PK; Bhattacharyya NK; Pandey A; Gupta P
Indian J Pathol Microbiol; 2013; 56(3):216-20. PubMed ID: 24152497
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Imatinib Treatment in Elderly Patients With Chronic Myeloid Leukemia: Real-Life Data and a Single-Center Experience.
Eşkazan AE; Özmen D; Öztaş M; Bektaş F; Bayraktar EA; Sadri S; Keskin D; Özgür Yurttaş N; Elverdi T; Salihoğlu A; Ar MC; Öngören Ş; Başlar Z; Aydın Y; Soysal T
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):549-557. PubMed ID: 34052176
[TBL] [Abstract][Full Text] [Related]
7. Pattern of chronic myeloid leukemia in the imatinib era in a Sub-Saharan African setting.
Faye BF; Dieng N; Seck M; Gadji M; Gueye YB; Sy D; Toure SA; Sall A; Toure AO; Dieye TN; Diop S
Ann Hematol; 2016 Oct; 95(10):1603-10. PubMed ID: 27370991
[TBL] [Abstract][Full Text] [Related]
8. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
Jiang Q; Wang HB; Yu L; Gale RP
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
[TBL] [Abstract][Full Text] [Related]
9. Comorbidities and polypharmacy impact on complete cytogenetic response in chronic myeloid leukaemia elderly patients.
Iurlo A; Ubertis A; Artuso S; Bucelli C; Radice T; Zappa M; Cattaneo D; Mari D; Cortelezzi A
Eur J Intern Med; 2014 Jan; 25(1):63-6. PubMed ID: 24309387
[TBL] [Abstract][Full Text] [Related]
10. [Comorbidity profile and its impact on reported outcome in Chinese patients with chronic myeloid leukemia in chronic phase receiving tyrosine kinase-inhibitor therapy].
Yu L; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):533-539. PubMed ID: 30122010
[No Abstract] [Full Text] [Related]
11. Mortality and Vascular Events Among Elderly Patients With Chronic Myeloid Leukemia: A Retrospective Analysis of Linked SEER-Medicare Data.
Lang K; McGarry LJ; Huang H; Dorer D; Kaufman E; Knopf K
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):275-285.e1. PubMed ID: 27013180
[TBL] [Abstract][Full Text] [Related]
12. [Cytogenetic response as a marker of efficacy of chronic myeloid leukemia therapy with a BCR-ABL thyrosine kinase inhibitor glivek].
Turkina AG; Kruglov SS; Druzhkova GA; Domracheva EV; Zakharova AV; Vinogradova OIu; Sysoeva EP; Diachenko LV; Chelysheva EIu; Zakharova ES; Abakumov EM; Kolosheĭnova TI; Kolosova LIu; Ivanova TV; Zhuravlev VS; Nemchenko IS; Zingerman BV; Kurova ES; Triputen' NZ; Loriia SS; Kovaleva LG; Khoroshko ND
Ter Arkh; 2005; 77(7):42-7. PubMed ID: 16116908
[TBL] [Abstract][Full Text] [Related]
13. Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.
Sasaki K; Kantarjian HM; Jain P; Jabbour EJ; Ravandi F; Konopleva M; Borthakur G; Takahashi K; Pemmaraju N; Daver N; Pierce SA; O'Brien SM; Cortes JE
Cancer; 2016 Jan; 122(2):238-48. PubMed ID: 26479889
[TBL] [Abstract][Full Text] [Related]
14. Chronic phase chronic myeloid leukemia: response of imatinib mesylate and significance of Sokal score, age and disease duration in predicting the hematological and cytogenetic response.
Usman M; Syed NN; Kakepoto GN; Adil SN; Khurshid M
J Assoc Physicians India; 2007 Feb; 55():103-7. PubMed ID: 17571738
[TBL] [Abstract][Full Text] [Related]
15. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
16. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
17. Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
Zhang XS; Gale RP; Huang XJ; Jiang Q
Leukemia; 2022 Feb; 36(2):482-491. PubMed ID: 34413457
[TBL] [Abstract][Full Text] [Related]
18. Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival.
Breccia M; Luciano L; Latagliata R; Castagnetti F; Ferrero D; Cavazzini F; Trawinska MM; Annunziata M; Stagno F; Tiribelli M; Binotto G; Crisà E; Musto P; Gozzini A; Cavalli L; Montefusco E; Iurlo A; Russo S; Cedrone M; Rossi AR; Pregno P; Endri M; Spadea A; Molica M; Giglio G; Celesti F; Sorà F; Storti S; D'Addosio A; Cambrin GR; Isidori A; Sica S; Abruzzese E; Speccha G; Rosti G; Alimena G
Leuk Res; 2014 Oct; 38(10):1173-6. PubMed ID: 25047978
[TBL] [Abstract][Full Text] [Related]
19. Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?
Gurrea Salas D; Glauche I; Tauer JT; Thiede C; Suttorp M
Ann Hematol; 2015 Aug; 94(8):1363-71. PubMed ID: 25894600
[TBL] [Abstract][Full Text] [Related]
20. Impact of risk score calculations in choosing front-line tyrosine kinase inhibitors for patients with newly diagnosed chronic myeloid leukemia in the chronic phase.
Hu B; Savani BN
Eur J Haematol; 2014 Sep; 93(3):179-86. PubMed ID: 24766312
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]